Impact of MS disease-modifying therapies on antibody and T cell responses following COVID-19 vaccination

被引：0

作者：

Sabatino, J. ^{[1
]}

Rowles, W. ^{[1
]}

Mittl, K. ^{[1
]}

Mcpolin, K. ^{[1
]}

Rajan, J. ^{[2
]}

Zamecnik, C. ^{[1
]}

Zhao, C. ^{[1
]}

Dandekar, R. ^{[1
]}

Alvarenga, B. ^{[1
]}

Loudermilk, R. ^{[1
]}

Gerungan, C. ^{[1
]}

Spencer, C. ^{[1
]}

Sagan, S. ^{[1
]}

Augusto, D. ^{[1
]}

Alexander, J. ^{[1
]}

Ho, B. ^{[1
]}

Hollenbach, J. ^{[1
]}

Zamvil, S. ^{[1
]}

Bove, R. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Neurol, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P979

引用

页码：795 / 795

页数：1

共 50 条

[21] Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown
Zrzavy, T.
Wimmer, I
Rommer, P. S.
Berger, T.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (10) : 3503 - 3516
[22] COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Reder, Anthony T.
Centonze, Diego
Naylor, Maria L.
Nagpal, Anjali
Rajbhandari, Rajani
Altincatal, Arman
Kim, Michelle
Berdofe, Aaron
Radhakrishnan, Maha
Jung, Eunice
Sandrock, Alfred W.
Smirnakis, Karen
Popescu, Catrinel
de Moor, Carl
CNS DRUGS, 2021, 35 (03) : 317 - 330
[23] Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Simpson-Yap, Steve
De Brouwer, Edward
Kalincik, Tomas
Rijke, Nick
Hillert, Jan A.
Walton, Clare
Edan, Gilles
Moreau, Yves
Spelman, Tim
Geys, Lotte
Parciak, Tina
Gautrais, Clement
Lazovski, Nikola
Pirmani, Ashkan
Ardeshirdavanai, Amin
Forsberg, Lars
Glaser, Anna
McBurney, Robert
Schmidt, Hollie
Bergmann, Arnfin B.
Braune, Stefan
Stahmann, Alexander
Middleton, Rodden
Salter, Amber
Fox, Robert J.
van der Walt, Anneke
Butzkueven, Helmut
Alroughani, Raed
Ozakbas, Serkan
Rojas, Juan, I
van der Mei, Ingrid
Nag, Nupur
Ivanov, Rumen
do Olival, Guilherme Sciascia
Dias, Alice Estavo
Magyari, Melinda
Brum, Doralina
Mendes, Maria Fernanda
Alonso, Ricardo N.
Nicholas, Richard S.
Bauer, Johana
Chertcoff, Anibal Sebastian
Zabalza, Anna
Arrambide, Georgina
Fidao, Alexander
Comi, Giancarlo
Peeters, Liesbet
NEUROLOGY, 2021, 97 (19) : E1870 - E1885
[24] COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Anthony T. Reder
Diego Centonze
Maria L. Naylor
Anjali Nagpal
Rajani Rajbhandari
Arman Altincatal
Michelle Kim
Aaron Berdofe
Maha Radhakrishnan
Eunice Jung
Alfred W. Sandrock
Karen Smirnakis
Catrinel Popescu
Carl de Moor
CNS Drugs, 2021, 35 : 317 - 330
[25] COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy
Wolf, Andrew
Alvarez, Enrique
NEUROLOGY-CLINICAL PRACTICE, 2021, 11 (04) : 358 - 361
[26] Effects of MS disease-modifying therapies on responses to vaccinations: A review
Ciotti, John Robert
Valtcheva, Manouela V.
Cross, Anne Haney
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 45
[27] COVID-19 pandemic: multiple sclerosis patients under disease-modifying therapies
Berger, T.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 58 - 58
[28] Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
Giovannoni, Gavin
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
[29] Antibody and T -Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients
How, Joan
Gallagher, Kathleen M. E.
Liu, Yiwen
DeMato, Ashley
Katsis, Katelin
Larson, Rebecca
Leick, Mark B.
Neuberg, Donna S.
Maus, Marcela V.
Hobbs, Gabriela
BLOOD, 2021, 138
[30] The Impact of Disease-Modifying Therapies of Multiple Sclerosis on the Effectiveness of the BBIBP-CorV COVID-19 Vaccine
Ghaffari, Mehran
Moghadam, Nahid Beladi
Paybast, Sepideh
Aghamiri, Seyed Hossein
Haghighi, Mehrdad
Javadi, Abdolreza
Rafatpanah, Houshang
Le, Saba Sadeghi Rashed
Nahayati, Mohammad Ali
ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2024, 19 (06):

← 1 2 3 4 5 →